PD-L1 IHC in NSCLC with a global and methodological perspective

Area of Science:

• Oncology
• Pathology
• Biomarker Research

Background:

• Programmed death-ligand 1 (PD-L1) is a key biomarker in cancer immunotherapy.
• Immunohistochemistry (IHC) is the primary method for detecting PD-L1 expression.
• Standardization of PD-L1 IHC assays is critical for clinical decision-making.

Purpose of the Study:

• To emphasize the significance of understanding immunohistochemistry (IHC) practices for the PD-L1 biomarker.
• To highlight the need for appropriate and accurate utilization of PD-L1 testing in patient care.
• To review the methodologic comparability of different PD-L1 IHC assays.

Main Methods:

• Review of current literature on PD-L1 IHC assays.
• Analysis of methodologic validation processes for laboratory-developed and commercial tests.
• Assessment of assay comparability from a methodologic standpoint.

Main Results:

• Current literature does not demonstrate comparability between different PD-L1 IHC assays from a methodologic perspective.
• Both laboratory-developed tests and commercial tests face similar challenges in validation.
• Rigorous methodologic execution is essential for reliable test outcomes.

Conclusions:

• Proper understanding and application of IHC for PD-L1 are vital for patient advantage.
• The lack of demonstrated comparability among assays necessitates careful validation.
• Ensuring accurate and representative test outcomes requires adherence to proper methodologic standards in assay validation.